SCHEMBL23289

SCHEMBL23289

O=C(Oc1[c]cccc1)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2 P00734 1/20 0.48
LMNA P02545 1/20 0.48
KMT2A Q03164 9/20 0.47
MAPT P10636 6/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
TSHR P16473 2/20 0.45
MEN1 O00255 4/20 0.44
TDP1 Q9NUW8 3/20 0.44
PARP10 Q53GL7 1/20 0.44
ALDH1A1 P00352 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
PKM P14618 1/20 0.42
SLC6A3 Q01959 1/20 0.42
TP53 P04637 1/20 0.41
JAK2 O60674 1/20 0.41
USP2 O75604 1/20 0.41
ESR1 P03372 1/20 0.41
GAA P10253 1/20 0.41
ALOX15 P16050 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9620982 0.87 SLC6A3 (0.59) LMNAKMT2AMAPTSMN1; SMN2TSHR
SCHEMBL25248 0.86 NPC1 (0.43) LMNAKMT2AMAPTSMN1; SMN2TSHR
SCHEMBL23380 0.82 ESR1 (0.52) LMNAKMT2AMAPTSMN1; SMN2MEN1
SCHEMBL7261346 0.82 L3MBTL1 (0.35) F2LMNAKMT2AMAPTSMN1; SMN2
SCHEMBL3231544 0.81 F2 (0.30) F2LMNA
SCHEMBL8201751 0.81 KMT2A (0.51) KMT2AMAPTTSHRMEN1TDP1
SCHEMBL5681417 0.80 F2 (0.44) F2LMNAKMT2AMAPTSMN1; SMN2
SCHEMBL7752627 0.80 TDP1 (0.35) KMT2AMAPTSMN1; SMN2MEN1TDP1
SCHEMBL7801460 0.78 LMNA (0.43) F2LMNAKMT2AMAPTSMN1; SMN2
SCHEMBL5551848 0.77 LMNA (0.64) F2LMNAKMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1619 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116096563-A Composition for electronic device encapsulation, method for forming electronic device encapsulation film, and electronic device encapsulation film 柯尼卡美能达株式会社 2023-05-09 CN claimed
CN-115806675-A Hydrogen bond organic framework material constructed based on carboxyl porphyrin ligand and preparation method and application thereof 中国科学院福建物质结构研究所 2023-03-17 CN claimed
CN-107155328-B Composition for display sealing material and display device containing the same 三星SDI株式会社 2022-05-31 CN claimed
EP-3241829-B1 HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES AS FUNGICIDES BAYER CROPSCIENCE AG (DE) 2020-12-23 EP claimed
US-10700133-B2 Organic light emitting display SAMSUNG SDI CO., LTD. (KR) 2020-06-30 US claimed
US-10570220-B2 Composition for display sealing material, organic protection layer comprising same, and display device comprising same SAMSUNG SDI CO., LTD. (KR) 2020-02-25 US claimed
CN-110669058-A Tricyclic quinolone carboxylic acid and preparation method thereof 江西农业大学 2020-01-10 CN claimed
CN-110194723-A A kind of N- Benzoylbenzene Isoserine derivatives and its synthetic method and application 华东师范大学 2019-09-03 CN claimed
US-10316112-B2 Composition for display sealing material, organic protection layer comprising same, and display device comprising same SAMSUNG SDI CO., LTD. (KR) 2019-06-11 US claimed
CN-105899216-B Pyrrolo [1,2-f ] [1,2,4] triazines useful for the treatment of respiratory syncytial virus infection 吉利德科学公司 2019-03-05 CN claimed
CN-1167105-A 1,4-diaryl-2-fluoro-2-butene insecticidal and acaricidal agents AMERICAN CYANAMID CO (US) 1997-12-10 CN claimed
EP-0321504-B1 CHIRAL ARYLOXY PROPIONIC ACID ESTERS AND THEIR USE AS DOPING AGENT IN LIQUID CRYSTAL PHASES HOECHST AKTIENGESELLSCHAFT (DE) 1992-01-08 EP claimed
US-4985172-A CONVERT SMECTIIC INTO FERROELECTRIC LIQUID CRYSTALS HOECHST AG (DE) 1991-01-15 US claimed
CN-1041942-A Pyridine derivate ICI PLC (GB) 1990-05-09 CN claimed
EP-0321504-A1 CHIRAL ARYLOXY PROPIONIC ACID ESTERS AND THEIR USE AS DOPING AGENT IN LIQUID CRYSTAL PHASES. HOECHST AG (DE) 1989-06-28 EP claimed
WO-1988003525-A1 CHIRAL ARYLOXY PROPIONIC ACID ESTERS AND THEIR USE AS DOPING AGENT IN LIQUID CRYSTAL PHASES HOECHST AKTIENGESELLSCHAFT (DE) 1988-05-19 WO claimed
EP-0009362-B1 HETEROCYCLIC DERIVATIVES OF GUANIDINE, THEIR PREPARATION AND PHARMACEUTICAL FORMULATIONS COMPRISING THEM McNeilab, Inc. (US) 1984-06-27 EP claimed
EP-0011372-B1 1-ACYLOXYPHENYL-1,2-DIPHENYLALKENE DERIVATIVES, PROCESSES FOR THEIR MANUFACTURE AND A PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1983-02-09 EP claimed
US-4275201-A Aryl substituted diketones STERLING DRUG INC. (US) 1981-06-23 US claimed
US-3988326-A Process for N-acylation of 7 amino cephem compounds MEIJI SEIKA KAISHA, LTD. (JA) 1976-10-26 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10316112-B2 Composition for display sealing material, organic protection layer comprising same, and display device comprising same ICAM1, CD40LG, VCAM1 F2 102/4885LMNA 1762/4885KMT2A 1174/4885
US-10570220-B2 Composition for display sealing material, organic protection layer comprising same, and display device comprising same TRPA1, ALKBH1, AHCYL1 F2 1027/4885LMNA 1819/4885KMT2A 1691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.